The tobacco industry is one of the most profitable markets for investors, given its large margins and shareholder returns. However, these past few years governments all over the world have been tightening up on regulatory laws and raising taxes, therefore reducing consumer volume of cigarettes. But the largest tobacco company worldwide, supported by investment gurus Joel Greenblatt (Trades, Portfolio) and Mario Gabelli (Trades, Portfolio), has successfully sustained its product demand and steadily increased revenue. So, let�� take a look at its business model and what the future holds in store.
A Powerful Brand Portfolio and Emerging Market Presence
Phillip Morris International Inc. (PM) is the world�� largest tobacco manufacturer in the world, after China National Tobacco, and holds 29% of the entire industry�� market, outside the U.S and China. Most commonly known for its flagship brand, Marlboro (accounts for one-third of total volume), this firm also owns seven of the 15 international leading cigarette brands. Its supporting brands ���&M, Phillip Morris, Bond Street, Parliament, Chesterfield and Lark ���ave allowed the company to attain consistent growth margins over the past decade. Given its addictive product and global manufacturing and distribution system, this comes as little surprise.
Top Performing Stocks To Buy For 2015: Unwired Planet Inc (UPIP)
Unwired Planet, Inc. (Unwired Planet), formerly Openwave Systems Inc., incorporated on December 16, 1994, is an intellectual property and technology licensing company. As of June 30, 2012, the Company had patent portfolio of approximately 200 issued United States and foreign patents and approximately 75 pending applications, many of which is considered foundational to mobile communications. In May 2012, the Company officially changed name to Unwired Planet, Inc.
On February 1, 2012, the Company sold its location business to Persistent Telecom Solutions Inc. On April 30, 2012, the Company completed the sale of its mediation and messaging product businesses to Openwave Mobility, Inc. The Company generates revenue by licensing its patented innovations and technologies to companies that develop mobile communications software infrastructure or hardware and/or develop mobile communications products.
Advisors' Opinion:- [By Wallace Witkowski]
Shares of Unwired Planet Inc. (UPIP) �jumped 75% to $2.27 on heavy volume after Lenovo Group (HK:0992) �said it would buy about 21 patent families from Unwired for $100 million.
- [By Anora Mahmudova]
Among individual stocks, Unwired Planet (UPIP) , an intellectual property company focused on the mobile industry, soared 49% after news that Chinese computer-maker Lenovo Group Ltd. (HK:0992) �was buying 21 of its patent families for $100 million.
Top 10 Integrated Utility Stocks For 2014: Alcoa Inc.(AA)
Alcoa, Inc. engages in the production and management of primary aluminum, fabricated aluminum, and alumina. The company operates in four segments: Alumina, Primary Metals, Flat-Rolled Products, and Engineered Products and Solutions. The Alumina segment engages in mining of bauxite, which is then refined into alumina. The Primary Metals segment produces aluminum. The Flat-Rolled Products segment engages in the production and sale of aluminum plate, sheet, and foil. The Engineered Products and Solutions segment produces and sells titanium, aluminum, and super alloy investment castings, hard alloy extrusions, forgings and fasteners, aluminum wheels, integrated aluminum structural systems, and architectural extrusions. Its products are used in aircraft, automobiles, commercial transportation, packaging, building and construction, oil and gas, defense, consumer electronics, and industrial applications. The company holds interests in bauxite mining activities. The company has op erations primarily in the United States, Australia, Spain, Brazil, the Netherlands, Norway, France, the Russian Federation, Hungary, Italy, the United Kingdom, China, and Germany. Alcoa, Inc. was founded in 1888 and is based in New York, New York.
Advisors' Opinion:- [By Reuters]
Andrew Harrer/Bloomberg via Getty ImagesThe Dow Jones news ticker in Times Square, New York City. NEW YORK -- Investment bank Goldman Sachs Group (GS), credit-card company Visa (V), and footwear Nike (NKE) will join the blue chip Dow Jones industrial average (^DJI) Dow Jones industrial average, the index managers said Tuesday, in the biggest shake-up for the 30-stock average in nearly a decade. The three companies will replace Bank of America (BAC), Hewlett-Packard (HPQ) and Alcoa (AA), all lower-priced stocks that exert a lesser pull on the price-weighted index. The changes will be effective on Sept. 23, S&P Dow Jones Indices said in a statement. The average, first established in 1896, includes 30 stocks, but very little money is indexed to its performance, unlike the broader Standard & Poor's 500 (^GSPC) or other indexes. In addition, because it is weighted by price, companies that are smaller in value with higher prices have more influence on the average. "Wow, those are big changes," said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, N.Y. "The Dow is really an antiquated index. It is price-weighted, which makes no sense. But there are still are some people that pay attention to it, and some technicians, so it has an influence on some people." Google (GOOG) and other names were considered for inclusion but passed over because of high stock prices, David Blitzer, managing director and chairman of the S&P Index Committee, told CNBC. The index manager said the changes were prompted by the low stock price of the three companies slated for removal and a desire to diversify the make-up of the index. Alcoa, in particular, has been seen as a candidate for elimination for some time, as the stock's market value of $8.5 billion is easily the lowest in the average. It is the first three-for-three change to the index since April 8, 2004, when American International Group (AIG), Pfizer (PFE) and Verizon (VZ) replaced AT&
- [By Paul Ausick]
The issue has been simmering for a few years now, really ever since aluminum came off its highs of 2006 and 2007. As banks were allowed to get into the trading of physical commodities in 2003, acquiring warehouses and charging for storage has been a nice profit maker. The banks are charged with failing to fill orders from customers�promptly, causing delays that then force those customers — who already own the aluminum in the warehouse — to buy the metal on the spot market from producers like Alcoa Inc. (NYSE: AA) and Rio Tinto PLC (NYSE: RIO).
- [By Jan-e- Alam]
Aluminum demand is expected to be strong in 2014. Top U.S. aluminum producer�Alcoa (NYSE: AA ) �expects global demand growth of 7% and is projecting a deficit of 730,000 tons for the year. Alcoa expects the aerospace market to register the strongest growth in demand, followed by automotive.�
- [By John Divine]
Lastly, aluminum giant Alcoa (NYSE: AA ) saw shares gain 2.3% as the materials sector soared higher today. Not only did Alcoa start the earnings season off on Monday with better-than-expected results, but Bernanke's comments yesterday sparked demand in the metals market. With the dollar weakening on news of continuing easing efforts, metals prices rose as investors put their money elsewhere. Not a single stock in the Dow ended the day in the red.
Top 10 Integrated Utility Stocks For 2014: EPAM Systems Inc (EPAM)
EPAM Systems, Inc. (EPAM), incorporated on December 18, 2002, is a global information technology (IT) services provider focused on software product development services, software engineering and vertically-oriented custom development solutions. EPAM has been serving independent software vendors (ISVs), and technology companies. These companies produce advanced software and technology products that demand software engineering talent, tools, methodologies and infrastructure to deliver solutions. Its service offerings cover the full software development lifecycle from complex software development services through maintenance and support, custom application development, application testing, enterprise application platforms and infrastructure management. Its key service offerings include software product development services, custom application development services, application testing services, enterprise application platforms, application maintenance and support and infrastructure management services. In December 2012, the Company acquired Empathy Lab.
Software Product Development Services
EPAM provides a set of software product development services, including product research, design and prototyping, product development, component design and integration, full lifecycle software testing, product deployment and end-user customization, performance tuning, product support and maintenance, as well as porting and cross-platform migration. The Company focuses on development services for enterprise software products covering a range of business applications, as well as product development for multiple mobile platforms and embedded software product services.
Custom Application Development Services
EPAM offers custom application development services. The Company�� range of services includes business and technical requirements analysis, solution architecture creation and validation, development, component design and integration, quality assurance and testing, d! eployment, performance tuning, support and maintenance, legacy applications re-engineering/refactoring, porting and cross-platform migration and documentation.
Application Testing Services
The Company�� application testing services include software application testing, including test automation tools and frameworks, and testing for enterprise IT, including test management, automation, functional and non-functional testing, as well as defect management. It also includes and consulting services focused on helping clients improve their existing software testing and quality assurance practices.
Enterprise Application Platforms
As a provider of software product development services to ISVs, EPAM has developed industry standard technology and business application platforms and their components in such areas as customer relationship management and sales automation, enterprise resource planning, enterprise content management, business intelligence, e-commerce, mobile, Software-as-a-Service and cloud deployment. The Company offers services around Enterprise Application Platforms, which include requirements analysis and platform selection, deep and complex customization, cross-platform migration, implementation and integration, as well as support and maintenance.
Application Maintenance and Support
EPAM delivers application maintenance and support services. The Company�� application maintenance and support offerings meet rigorous CMMI and SAS 70 Type II requirements. Its services include incident management, fault investigation diagnosis, work-around provision, application bug fixes, release management, application enhancements and third-party maintenance.
Infrastructure Management Services
EPAM service offerings cover infrastructure management services. The Company has implemented large infrastructure monitoring solutions, providing real-time notification and control from the low-level infrastructure up! to and i! ncluding applications. Its solutions cover the lifecycle of infrastructure management, including application, database, network, server, storage and systems operations management, as well as incident notification and resolution.
Advisors' Opinion:- [By Seth Jayson]
EPAM Systems (NYSE: EPAM ) reported earnings on May 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), EPAM Systems met expectations on revenues and missed estimates on earnings per share.
Top 10 Integrated Utility Stocks For 2014: Eaton Vance Tax-Managed Diversified Equity Income Fund (ETY)
Eaton Vance Tax-Managed Diversified Equity Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The Fund invests primarily in a diversified portfolio of common stocks. The Fund will invest at least 80% of its total assets in a combination of dividend paying common stocks, and common stocks the value of which is subject to covered written index call options. It seeks to generate current earnings in part by writing (selling) stock index call options on the S&P 500 Index and investing in dividend-paying common stock. The Fund invests in sectors, such as financials, energy, information technology, industrials, healthcare, consumer staples, telecommunication services, consumer discretionary, materials and utilities.
The Fund�� investment advisor is Eaton Vance Management (EVM). Its sub-advisor is Rampart Investment Management. The Fund may invest in Cash Management Portfolio, an affiliated investment company managed by Boston Management and Research (BMR), a subsidiary of EVM.
Advisors' Opinion:- [By Robert Carlson]
This recommended fund is Eaton Vance Tax-Managed Diversified Equity Income (ETY). The options that the fund writes give buyers the right to buy the stocks from the fund at fixed prices by a certain date.
Top 10 Integrated Utility Stocks For 2014: Choice Hotels International Inc. (CHH)
Choice Hotels International, Inc., together with its subsidiaries, operates as a hotel franchisor worldwide. It franchises lodging properties under its proprietary brand names, including Comfort Inn, Comfort Suites, Quality, Clarion, Sleep Inn, Econo Lodge, Rodeway Inn, MainStay Suites, Suburban Extended Stay Hotel, Cambria Suites, and Ascend Collection brands. As of March 31, 2011, it operated 6,128 open hotels comprising 492,733 rooms, as well as 606 hotels consisting of 49,908 rooms under construction, awaiting conversion, or approved for development in 49 states, and the District of Columbia in the United States; and approximately 40 countries and other territories. The company was founded in 1981 and is based in Silver Spring, Maryland.
Advisors' Opinion:- [By John Udovich]
Small cap hotel stock La Quinta Holdings Inc (NYSE: LQ) just had its IPO to raise a lower than expected $650 million after being priced below its expected range, meaning its worth taking a closer look at the stock which�is focused on the�mid-priced hotel market along with the performance of potential benchmarks like hotel stocks Marriott International Inc (NASDAQ: MAR), Choice Hotels International Inc (NYSE: CHH) and Wyndham Worldwide Corporation (NYSE: WYN).
- [By Sean Williams]
Don't make the wrong Choice
I predict that 2013 will be the return of the "staycation." In the depths of the recession, instead of taking expensive getaways, consumers chose simply to take time off work and stay home or locally. I think we have the perfect confluence of factors that could make life difficult for Choice Hotels International (NYSE: CHH ) , operator of Comfort Inn, Comfort Suites, and a multitude of other mid-price-point hotels. - [By Jeremy Bowman]
What: Shares of Choice Hotels (NYSE: CHH ) were getting picked last by investors today, falling 11% after cutting EPS guidance in its quarterly report.
Top 10 Integrated Utility Stocks For 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Bryan Murphy]
Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.
- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
Top 10 Integrated Utility Stocks For 2014: Ellington Financial LLC (EFC)
Ellington Financial LLC (EFC) is a specialty finance company, which specializes in acquiring and managing mortgage-related assets. As of December 31, 2011, its targeted assets included residential mortgage-backed securities (RMBS), backed by prime jumbo, Alternative A-paper (Alt-A), manufactured housing and subprime residential mortgage loans (non-Agency RMBS); RMBS for which the principal and interest payments are guaranteed by a United States Government agency or a United States Government-sponsored entity (Agency RMBS); mortgage-related derivatives; commercial mortgage-backed securities (CMBS), commercial mortgage loans and other commercial real estate debt, and corporate debt and equity securities and derivatives. It also acquires and manages other types of mortgage-related assets and financial assets, such as residential whole mortgage loans, asset-backed securities (ABS), backed by consumer and commercial assets, non-mortgage-related derivatives and real property.
Non-Agency RMBS
The Company acquires non-Agency RMBS backed by prime jumbo, Alt-A, manufactured housing and subprime residential mortgage loans. Its non-Agency RMBS holdings include investment-grade and non-investment grade classes. Non-Agency RMBS are debt obligations issued by private originators of or investors in residential mortgage loans. Non-Agency RMBS are issued as CMOs and are backed by pools of whole mortgage loans or by mortgage pass-through certificates. Non-Agency RMBS are securitized in senior/subordinated structures, or in excess spread/over-collateralization structures. In senior/subordinated structures, the subordinated tranches absorb all losses on the underlying mortgage loans before any losses are borne by the senior tranches.
Agency RMBS
The Company�� assets in this asset class consist of whole pool pass-through certificates, the principal and interest of which are guaranteed by Federal National Mortgage Association (Fannie Mae), Federal Home Loan Mortgage Cor! poration (Freddie Mac), or Government National Mortgage Association (Ginnie Mae), and which are backed by adjustable rate mortgages (ARMs), hybrid ARMs or fixed-rate mortgages. Mortgage pass-through certificates are securities representing undivided interests in pools of mortgage loans secured by real property where payments of both interest and principal, plus pre-paid principal, on the securities are made monthly to holders of the security, in effect passing through monthly payments made by the individual borrowers on the mortgage loans that underlie the securities, net of fees paid to the issuer/guarantor and servicers of the securities. Whole pool pass-through certificates are mortgage pass-through certificates that represent the entire ownership of a pool of mortgage loans.
In addition to investing in specific pools of Agency RMBS, the Company utilizes forward-settling purchases and sales of Agency RMBS where the underlying pools of mortgage loans are to be announced mortgage-backed securities (MBS) (TBAs). Pursuant to these TBA transactions, it agrees to purchase or sell, for future delivery, Agency RMBS with certain principal and interest terms and certain types of underlying collateral. It uses TBAs for hedging purposes. It engages in TBA transactions for purposes of managing certain risks associated with its long Agency RMBS and its non-Agency RMBS.
Mortgage-Related Derivatives
The Company takes long and short positions in various mortgage-related derivative instruments, including credit default swaps. A credit default swap is a credit derivative contract in which one party (the protection buyer) pays an ongoing periodic premium (and often an upfront payment as well) to another party (the protection seller) in return for compensation for default (or similar credit event) by a reference entity. In this case, the reference entity can be an individual MBS or an index of several MBS, such as an ABX Index, PrimeX or a CMBX Index.
CMBS
CMBS ar! e mortgage-backed securities collateralized by loans on commercial properties. CMBS issued are fixed rate securities backed by fixed rate loans made to multiple borrowers on a range of property types, though single-borrower CMBS and floating-rate CMBS have also been issued. Commercial mortgage loans are loans secured by liens on commercial properties, including retail, office, industrial, hotel and multifamily properties. Commercial real estate loans may also be structured into more complicated senior/subordinate structures, including those providing for multiple B-Note or multiple mezzanine loan senior/subordinate components.Corporate Debt and Equity Securities and Derivatives
For hedging purposes, the Company takes short positions in corporate debt and equity (including indices on corporate debt and equity) by entering into derivative contracts, such as credit default swaps, total return swaps and options. These hedges reference corporations (such as financial institutions that have substantial mortgage-related exposure) or indices whose performance has a degree of correlation with the performance of its portfolio. Given this correlation, a short position with respect to such corporations or indices provides a hedge to its portfolio of MBS as a whole.
Other Assets
The Company from time to time acquires other mortgage-related and financial assets, which include residential whole mortgage loans, ABS backed by consumer and commercial assets and real property. It also acquires real property interests, such as single family and multifamily residential properties.
Advisors' Opinion:- [By Luke Jacobi]
Ellington Financial LLC (NYSE: EFC) was down, falling 4.4 percent to $23.53 after the company priced 8 million shares at $23.92 per share.
CommoditiesAlthough equities have been flat, the same cannot be said for the commodity market. Crude futures shot higher Wednesday, following yesterday’s sharp sell off. At last check, WTI futures were up 2.7 percent to $95.37 and Brent futures gained 2.1 percent to $102.45.
No comments:
Post a Comment